It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...

Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what is so special about it ...

About four years after launch, Orna Therapeutics Inc. signed its second major deal, this time validating the lipid nanoparticle delivery technology it acquired through its Renagade Therapeutics Inc.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech ...

Ratings for Vertex Pharmaceuticals (NASDAQ ... a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute ...

If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock ...

Vertex Pharmaceuticals Incorporated today announced multiple program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 43rd Annual J.P. Morgan ...